Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies
Epilepsia · 2024
DOI: 10.1111/epi.18020 ↗Kurz gefasst
Scoping Review in der Zeitschrift Epilepsia, 2024. Verfasst von Antonio Gil-Nagel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Ruber Internacional, Madrid, Spain. Hauptthemen laut MEDLINE: Fenfluramine, Lennox Gastaut Syndrome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Developmental and epileptic encephalopathies (DEEs) are characterized by pharmacoresistant seizures and developmental delay. Patients with DEEs experience multiple seizure types, including tonic–clonic seizures (TCS) that can be generalized tonic–clonic (GTCS) or focal evolving to bilateral tonic–clonic (FBTCS). Fenfluramine (FFA) has demonstrated efficacy in reduction of TCS in patients with Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and other DEEs. Using the PRISMA‐ScR (Preferred Reporting Items for Systematic Review and Meta‐Analyses extension for Scoping Review) guidelines, we performed a scoping review to describe changes in TCS in patients treated with FFA. A comprehensive search of five literature databases was conducted up to February 14, 2023. Studies were included if they reported change in GTCS or TCS (but not FBTCS) after treatment with FFA in patients with DEEs. Duplicate patients and studies with unclear efficacy data were excluded. Fourteen of 422 studies met the eligibility criteria. Data extracted and evaluated by expert clinicians identified 421 unique patients with DS (in nine studies), CDKL5 deficiency disorder, SCN8A‐ related disorder, LGS, SCN1B ‐related disorder, and other DEEs. The median percent reduction in GTCS or TCS from baseline was available in 10 studies ( n = 328) and ranged from 47.2% to 100%. Following FFA treatment, 10 studies ( n = 144) reported ≥50% reduction in GTCS or TCS from baseline in 72% of patients; in nine of those ( n = 112), 54% and 29% of patients achieved ≥75% and 100% reduction in GTCS or TCS from baseline, respectively. Overall, this analysis highlighted improvements in GTCS or TCS frequency when patients were treated with FFA regardless of the DEE evaluated. Future studies may confirm the impact of FFA on TCS reduction and on decreased premature mortality risk (including sudden unexpected death in epilepsy), improvement in comorbidities and everyday executive function, decreased health care costs, and improvement in quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Ruber Internacional, Madrid, Spain.
- University College London (UCL) National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC) Great Ormond Street Institute of Child Health, London, UK.
- New York University Langone Medical Center, New York, New York, USA.
- University of Antwerp, Edegem, Belgium.
- University of Leuven, Leuven, Belgium.
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
ORCID-Profile: Antonio Gil-Nagel, J Helen Cross, Orrin Devinsky, Lieven Lagae, Kelly Knupp, An-Sofie Schoonjans, Philippe Ryvlin, Elizabeth A Thiele, Amélie Lothe, Rima Nabbout
Förderung
- UCB Pharma
Zitieren
APA
Gil-Nagel, A., Cross, J. H., Devinsky, O., Ceulemans, B., Lagae, L., Knupp, K., Schoonjans, A. S., Ryvlin, P., Thiele, E. A., Polega, S., Lothe, A., & Nabbout, R. (2024). Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies. Epilepsia. https://doi.org/10.1111/epi.18020
Vancouver
Gil-Nagel A, Cross JH, Devinsky O, Ceulemans B, Lagae L, Knupp K, et al. Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies. Epilepsia. 2024. doi:10.1111/epi.18020
BibTeX
@article{GilNagel2024,
author = {Gil-Nagel, Antonio and Cross, J Helen and Devinsky, Orrin and Ceulemans, Berten and Lagae, Lieven and Knupp, Kelly and Schoonjans, An-Sofie and Ryvlin, Philippe and Thiele, Elizabeth A and Polega, Shikha and Lothe, Amélie and Nabbout, Rima},
title = {Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.18020}
}
EUVIMED